Interestingly, the latest research reported that METTL3 expression is positively associated with a higher grade and poorer prognosis of isocitrate dehydrogenase (IDH)-wildtype glioma but not IDH-mutant glioma. This evidence concerns the gene IDH1 and central nervous system cancer.